Phenomix Starts Phase 1a Clinical Trial Of Hepatitis C Protease Inhibitor PHX1766

Phenomix Corporation today announced it has begun administering subjects in a Phase 1a clinical trial of PHX1766, the company’s internally discovered, orally available NS3/4A protease inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. The study is being conducted at clinical sites in the Netherlands and will enroll approximately 24 healthy subjects and six HCV infected patients.

More: continued here

Filed under: Clinical Trials on October 29th, 2008